Nature's Sunshine Products Stock Forecast
NASDAQ: NATRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 9:42 AM ET
NATR analyst consensus
Consensus (2 analysts)
none
Avg. price target
$30.50+140.44%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering Nature's Sunshine Products (2026-10-08), 2 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $30.50, with a high estimate of $36.00 and a low estimate of $25.00. The average target implies upside of 140.4% from the current price of $12.69.
The spread between the highest and lowest targets is 44.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NATR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $25.00 | +97.08% |
| Average target | $30.50 | +140.44% |
| High target | $36.00 | +183.80% |